ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study

The goal of this clinical trial is to explore the disease-free survival period of elderly patients with high-risk stage II and stage III colon cancer based on ctDNA detection. The main questions it aims to answer are: Can ctDNA detection effectively guide the assessment of disease-free survival in elderly patients with high-risk stage II and stage III colon cancer? What is the correlation between postoperative ctDNA status and patient imaging as well as prognosis in elderly patients? Secondary objectives include: Evaluating the correlation between postoperative ctDNA status and patient imag

Trial Details

NCT ID
NCT06609551
Phase
PHASE3
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • 6-month adjuvant chemotherapy with 5-FU monotherapy
  • XELOX intensive treatment group
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Patients aged 70-80, both male and female are eligible;
  • Patients with histopathologically confirmed stage II high-risk or stage III colon cancer;
  • Patients with an ECOG score of ≤2;
  • Patients who are required to undergo tissue genetic testing;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →